K. Aaltonen

发表

Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.

J. Askling, K. Hellgren, C. Ballegaard, 2021, Rheumatology.

Efficacy, Safety and Clinical Outcomes of Biologic Drugs in the Treatment of Rheumatoid Arthritis

K. Aaltonen, 2015 .

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.

T. Sokka, D. Nordström, K. Aaltonen, 2016, Rheumatology.

Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.

Y. Konttinen, T. Sokka, D. Nordström, 2013, Seminars in arthritis and rheumatism.

Rheumatoid Arthritis Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis ? A register-based study

Y. Konttinen, T. Sokka, D. Nordström, 2013 .

Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.

L. Jacobsson, J. Askling, T. Kvien, 2020, Rheumatology.

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

J. Askling, B. Delcoigne, R. Cordtz, 2020, RMD Open.

Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice

P. Isomäki, D. Nordström, K. Aaltonen, 2017, Rheumatology.

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.

W. Dixon, M. A. van de Laar, P. V. van Riel, 2015, Rheumatology.

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis

L. Jacobsson, J. Askling, D. Nordström, 2019, RMD Open.

One‐Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses

L. Jacobsson, J. Askling, D. Nordström, 2020, Arthritis care & research.

Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study

M. Pertovaara, D. Nordström, K. Aaltonen, 2015, The Journal of Rheumatology.

Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy

Y. Konttinen, T. Sokka, D. Nordström, 2015, The Journal of Rheumatology.

Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study

J. Askling, P. Isomäki, K. Hellgren, 2022, RMD Open.

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example

L. Jacobsson, J. Askling, T. Kvien, 2018, RMD Open.

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

Antti Malmivaara, Yrjö T. Konttinen, A. Malmivaara, 2012, PloS one.

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review

Y. Konttinen, D. Nordström, K. Aaltonen, 2015, PloS one.

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

J. Rutanen, D. Nordström, K. Aaltonen, 2019, PloS one.

Impact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study

J. Rutanen, D. Nordström, K. Aaltonen, 2023, Rheumatology advances in practice.

Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.

T. Sokka, D. Nordström, K. Aaltonen, 2017, Seminars in arthritis and rheumatism.

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers

J. Askling, K. Hellgren, B. Delcoigne, 2023, RMD Open.

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers

L. Jacobsson, D. D. Giuseppe, J. Askling, 2018 .

FRI0082 EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND RITUXIMAB) AFTER FAILURE OF NON-TNFI BIOLOGIC DMARD IN RHEUMATOID ARTHRITIS –COLLABORATION BETWEEN FIVE NATIONAL REGISTERS

L. Jacobsson, D. D. Giuseppe, J. Askling, 2019, Poster Presentations.

Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland

P. Isomäki, T. Sokka, D. Nordström, 2017, Scandinavian journal of rheumatology.

Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort

H. Mäkinen, P. Hannonen, H. Kautiainen, 2017, Scandinavian journal of rheumatology.